Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Rev Med Brux ; 36(4): 212-8, 2015 Sep.
Article in French | MEDLINE | ID: mdl-26591303

ABSTRACT

Newborn screening is a public health effort that has changed the prognosis of some congenital diseases. Newborn screening programmes differ between countries in which it is organized. Demographic, epidemiological or economic factors play a role in the choice of the screening panel. In the French Community of Belgium, the programme focuses on 13 metabolic and endocrine diseases, hearing loss and hemoglobinopathies (Brussels and Liege). Newborn screening is a complex process that requires the involvement of all stakeholders : parent information, blood sampling or testing, lab analysis, follow-up of the results, initiate adequate care in case of positive test and genetic counselling. Newborn screening programmes will evolve in the next years. New therapeutic and diagnostic methods will make other genetic diseases candidates for screening. Whole genome sequencing may be the next expansion; it will create new opportunities but will pose new ethical dilemmas. We must all prepare now for future challenges.


Subject(s)
Neonatal Screening , Pediatrics , Physician's Role , Female , Hearing Loss , Hearing Tests , Humans , Infant, Newborn , Neonatal Screening/methods , Neonatal Screening/statistics & numerical data , Pregnancy
2.
Eur J Pediatr ; 173(10): 1365-71, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24764116

ABSTRACT

UNLABELLED: Growing-up milks (GUM) are milk-based drinks with low protein and added minerals and vitamins intended for children 12-36 months. Since the advantages of GUM are heavily debated, we reviewed the literature. A literature search was done using the classic databases (Pubmed, Embase, Cochrane) on the use of GUM in 12- to 36-month-old young children. Only limited data are available. GUM have a highly variable composition as their marketing is not regulated. Nevertheless, all papers conclude that GUM help to cover nutritional requirements of 12- to 36-month-old infants. CONCLUSION: Appropriate intakes of macro- and micronutrients in 1- to 3-year-old children have long-term health benefits. Present diets offered to toddlers do in general not meet the requirements. Supplemented foods are therefore helpful, of which GUM is a possibility.


Subject(s)
Child Nutritional Physiological Phenomena , Food, Fortified , Milk , Minerals , Nutritional Requirements , Vitamins , Animals , Belgium , Child, Preschool , Humans , Infant
3.
Mol Genet Metab ; 110 Suppl: S6-17, 2013.
Article in English | MEDLINE | ID: mdl-24113686

ABSTRACT

Patients with phenylketonuria (PKU) encompass an 'at risk' group for micronutrient imbalances. Optimal nutrient status is challenging particularly when a substantial proportion of nutrient intake is from non-natural sources. In PKU patients following dietary treatment, supplementation with micronutrients is a necessity and vitamins and minerals should either be added to supplement phenylalanine-free l-amino acids or given separately. In this literature review of papers published since 1990, the prevalence of vitamin and mineral deficiency is described, with reference to age of treatment commencement, type of treatment, dietary compliance, and dietary practices. Biological micronutrient inadequacies have been mainly reported for zinc, selenium, iron, vitamin B12 and folate. The aetiology of these results and possible clinical and biological implications are discussed. In PKU there is not a simple relationship between the dietary intake and nutritional status, and there are many independent and interrelated complex factors that should be considered other than quantitative nutritional intake.


Subject(s)
Dietary Supplements , Micronutrients/deficiency , Minerals/administration & dosage , Nutritional Status , Phenylketonurias/physiopathology , Vitamin B 6 Deficiency/etiology , Vitamins/administration & dosage , Adolescent , Adult , Aging , Child , Child, Preschool , Female , Humans , Infant , Male , Micronutrients/administration & dosage , Nutritional Requirements , Patient Compliance , Phenylketonurias/complications , Phenylketonurias/diet therapy , Young Adult
4.
Mol Genet Metab ; 110 Suppl: S1-5, 2013.
Article in English | MEDLINE | ID: mdl-24018009

ABSTRACT

For almost all patients with PKU, a low phenylalanine diet is the basis of the treatment despite a widely varying natural protein tolerance. A vitamin and mineral supplement is essential and it is commonly added to a phenylalanine-free (phe-free) source of L-amino acids. In PKU, many phe-free L-amino acid supplements have age-specific vitamin and mineral profiles to meet individual requirements. The main micronutrient sources are chemically derived and their delivery dosage is usually advised in three or more doses throughout the day. Within the EU, the composition of VM (vitamin and mineral) phe-free L-amino acid supplements is governed by the Foods for Special Medical Purposes (FSMP) directive (European Commission Directive number 1999/21/EC and amended by Directive 2006/141/EC). However the micronutrient composition of the majority fails to remain within FSMP micronutrient maximum limits per 100 kcal due to their low energy content and so compositional exceptions to the FSMP directive have to be granted for each supplement. All patients with PKU require an annual nutritional follow-up, until it has been proven that they are not at risk of any vitamin and mineral imbalances. When non-dietary treatments are used to either replace or act as an adjunct to diet therapy, the quality of micronutrient intake should still be considered important and monitored systematically. European guidelines are required about which micronutrients should be measured and the conditions (fasting status) for monitoring.


Subject(s)
Micronutrients/administration & dosage , Minerals/administration & dosage , Phenylketonurias/diet therapy , Vitamins/administration & dosage , Dietary Supplements , European Union , Humans , Micronutrients/adverse effects , Minerals/adverse effects , Phenylalanine/deficiency , Phenylalanine/metabolism , Vitamins/adverse effects
5.
Rev Med Brux ; 33(4): 318-27, 2012 Sep.
Article in French | MEDLINE | ID: mdl-23091937

ABSTRACT

Exclusive breastfeeding is recommended up to 6 months of age, and may be continued in combination with a more diversified diet until 2 years of age. It represents the ideal natural diet for the newborn. The current change of maternity care policy and the adherence to the Baby Friendly Hospital Initiative (BFHI) project, have been associated with a significant improvement of patient information. This positive aspect combined with the effect of perinatal education were major contributors for breastfeeding promotion. This article presents the physiology of breastfeeding and its practical aspects, useful for the family doctor. The doctor plays a central role both in the information, which might influence the choice of breastfeeding, and also in the support of the mother or her baby. The duration of breastfeeding represents the new goal to be emphasized. Lactating mothers should be encouraged to consult competent caregivers, including the family doctor in case of breastfeeding difficulties.


Subject(s)
Breast Feeding , Lactation/physiology , Breast/metabolism , Breast/physiology , Breast Feeding/adverse effects , Breast Feeding/methods , Contraindications , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Infant, Newborn , Maternal Exposure/adverse effects , Milk, Human/physiology , Models, Biological , Mother-Child Relations , Smoking/adverse effects
6.
Cell Transplant ; 21(12): 2765-70, 2012.
Article in English | MEDLINE | ID: mdl-22889463

ABSTRACT

Phenylketonuria is a metabolic disease caused by phenylalanine hydroxylase deficiency. Treatment is based on a strict natural protein-restricted diet that is associated with the risk of malnutrition and severe psychosocial burden. Oral administration of tetrahydrobiopterin can increase residual enzyme activity, but most patients with severe clinical phenotypes are nonresponders. We performed liver cell transplantation in a 6-year-old boy with severe tetrahydrobiopterin nonresponsive phenylketonuria who failed to comply with diet prescriptions. The transplanted hepatocytes were obtained in part from an explanted glycogen storage type 1b liver. Following two infusions, blood phenylalanine levels returned within the therapeutic target while the phenylalanine half-life assessed by loading tests decreased from 43 to 19 h. However, 3 months later, blood phenylalanine concentrations increased and the phenylalanine intake had to be reduced. Cell-based therapy is a promising therapeutic option in phenylketonuria, and the domino concept may solve the issue of cell sources for hepatocyte transplantation.


Subject(s)
Hepatocytes/transplantation , Phenylketonurias/therapy , Cell- and Tissue-Based Therapy , Child , Female , Glycogen Storage Disease Type I/therapy , Half-Life , Hepatocytes/cytology , Humans , Infant , Liver Function Tests , Male , Phenylalanine/blood , Phenylalanine Hydroxylase/genetics , Phenylalanine Hydroxylase/metabolism , Phenylketonurias/diagnosis
7.
JIMD Rep ; 4: 103-8, 2012.
Article in English | MEDLINE | ID: mdl-23430903

ABSTRACT

We describe a 27-month-old girl with COG6 deficiency. She is the first child of healthy consanguineous Moroccan parents. She presented at birth with dysmorphic features including microcephaly, post-axial polydactyly, broad palpebral fissures, retrognathia, and anal anteposition. The clinical phenotype was further characterised by multiorgan involvement including mild psychomotor retardation, and microcephaly, chronic inflammatory bowel disease, micronodular liver cirrhosis, associated with life-threatening and recurrent infections due to combined T- and B-cell dysfunction and neutrophil dysfunction.Mutation analysis showed the patient to be homozygous for the c.G1646T mutation in the COG6 gene. She is the second reported patient with a deficiency of subunit 6 of the COG complex. Although both patients are homozygous for the same mutation, they present a markedly different clinical picture. Indeed immunodeficiency as well as inflammatory bowel disease has not been described previously in patients with any COG-CDG.

9.
Eur J Clin Nutr ; 60(8): 978-84, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16482073

ABSTRACT

OBJECTIVE: To compare the effects of alpha-linolenic acid (ALA, C18:3n-3) to those of eicosapentaenoic acid (EPA, C20:5n-3) plus docosahexaenoic acid (DHA, C22:6n-3) on cardiovascular risk markers in healthy elderly subjects. DESIGN: A randomized double-blind nutritional intervention study. SETTING: Department of Human Biology, Maastricht University, the Netherlands. SUBJECTS: Thirty-seven mildly hypercholesterolemic subjects, 14 men and 23 women aged between 60 and 78 years. INTERVENTIONS: During a run-in period of 3 weeks, subjects consumed an oleic acid-rich diet. The following 6 weeks, 10 subjects remained on the control diet, 13 subjects consumed an ALA-rich diet (6.8 g/day) and 14 subjects an EPA/DHA-rich diet (1.05 g EPA/day + 0.55 g DHA/day). RESULTS: Both n-3 fatty acid diets did not change concentrations of total-cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerol and apoA-1 when compared with the oleic acid-rich diet. However, after the EPA/DHA-rich diet, LDL-cholesterol increased by 0.39 mmol/l (P = 0.0323, 95% CI (0.030, 0.780 mmol/l)) when compared with the ALA-rich diet. Intake of EPA/DHA also increased apoB concentrations by 14 mg/dl (P = 0.0031, 95% CI (4, 23 mg/dl)) and 12 mg/dl (P = 0.005, 95% CI (3, 21 mg/dl)) versus the oleic acid and ALA-rich diet, respectively. Except for an EPA/DHA-induced increase in tissue factor pathway inhibitor (TFPI) of 14.6% (P = 0.0184 versus ALA diet, 95% CI (1.5, 18.3%)), changes in markers of hemostasis and endothelial integrity did not reach statistical significance following consumption of the two n-3 fatty acid diets. CONCLUSIONS: In healthy elderly subjects, ALA might affect concentrations of LDL-cholesterol and apoB more favorably than EPA/DHA, whereas EPA/DHA seems to affect TFPI more beneficially.


Subject(s)
Cardiovascular Diseases/blood , Cholesterol/blood , Fatty Acids, Omega-3/pharmacology , Hypercholesterolemia/diet therapy , Lipoproteins/blood , alpha-Linolenic Acid/pharmacology , Aged , Apolipoprotein A-I/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Docosahexaenoic Acids/blood , Docosahexaenoic Acids/pharmacology , Double-Blind Method , Eicosapentaenoic Acid/blood , Eicosapentaenoic Acid/pharmacology , Fatty Acids, Omega-3/blood , Female , Humans , Hypercholesterolemia/blood , Lipoproteins/drug effects , Male , Middle Aged , Oleic Acid/pharmacology , Risk Factors , Treatment Outcome , Triglycerides/blood , alpha-Linolenic Acid/blood
10.
Rev Med Brux ; 27 Spec No: Sp74-7, 2006.
Article in French | MEDLINE | ID: mdl-21818897

ABSTRACT

The concept "inborn error of metabolism" (IEM) arose from the observations of Sir A. Garrod at the beginning of the XXth century. The exponential development, during the last decades, of our knowledge in cellular biology and molecular genetics, and the availability of increasingly more precise diagnostic tools, allow the identification of a still growing number of inborn errors of metabolism. Their physiopathology is better understood. Treatments have considerably improved: more specific diets, new medical treatments, enzyme replacement therapy, organ transplantation, hepatocyte or stem cell transplantation... New techniques are under development, including various strategies of gene therapy. Improved therapeutic efficacy combined with earlier diagnosis have dramatically changed the prognosis of many disorders. As a consequence, new challenging questions have to be answered. Today, patients with an IEM, because of the extreme complexity of their management, need to be looked after by a multidisciplinary team of physicians (pediatricians and internists), dieticians, social workers, psychologists... It is essential, in this complex and rapidly expanding field, that experiences should be shared at national and international level, in order to provide the most adequate care for patients.


Subject(s)
Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/therapy , Humans , Infant, Newborn , Metabolism, Inborn Errors/genetics , Neonatal Screening
12.
Clin Sci (Lond) ; 103(6): 559-66, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12444908

ABSTRACT

Recently, we observed that impairments exist in skeletal muscle free fatty acid (FFA) utilization during exercise in obese subjects with Type II diabetes. The main objective of the present study was to investigate whether plasma FFA oxidation is impaired during exercise in non-obese Type II diabetic patients. Stable isotope tracers of palmitate and glucose were infused for 2 h at rest and 1h of bicycle exercise at 40% peak oxygen consumption ( V*O(2)max) in volunteers with Type II diabetes and a healthy control group. At rest, plasma FFA oxidation was not significantly different between subjects with Type II diabetes and control subjects (2.13+/-0.51 versus 1.93+/-0.54 micromol.kg(-1).min(-1) respectively). During exercise, Type II diabetic patients and control subjects had similar rates of total fat [Type II diabetes, 9.62+/-1.84 micromol.kg(-1).min(-1); control, 12.08+/-4.59 micromol.kg(-1).min(-1); not significant (NS)] and glucose oxidation (Type II diabetes, 44.24+/-10.36 micromol.kg(-1).min(-1); control, 57.37+/-14.54 micromol.kg(-1).min(-1); NS). No aberrations were present in plasma FFA uptake [rate of disappearance ( Rd ); Type II diabetes, 11.78+/-4.82; control, 10.84+/-3.39; NS] and oxidation rates (Type II diabetes 8.10+/-1.44; control 8.00+/-3.12, NS) in Type II diabetic patients; triacylglycerol-derived fatty acid oxidation was 2.6-fold lower in Type II diabetic patients than in control subjects, but this difference was not statistically significant. Muscle glycogen oxidation was lower in diabetes patients than in control subjects (Type II diabetes, 25.16+/-13.82 micromol.kg(-1).min(-1); control, 42.04+/-10.58 micromol.kg(-1).min(-1); P <0.05) and plasma glucose contributed more to energy expenditure in Type II diabetes (26+/-3% in diabetic versus 15+/-2% in control, P <0.05). We conclude that plasma FFA oxidation is not impaired during exercise in non-obese Type II diabetic patients. The data confirm that Type II diabetes is a heterogeneous disease, and that the adaptation at the substrate level differs between obese and non-obese patients and may contribute to differences in the final appearance of the various phenotypes.


Subject(s)
Diabetes Mellitus, Type 2/blood , Exercise , Fatty Acids, Nonesterified/blood , Adult , Blood Glucose/metabolism , Case-Control Studies , Diabetes Mellitus, Type 2/physiopathology , Energy Metabolism , Glycogen/metabolism , Humans , Insulin/blood , Lipids/blood , Male , Middle Aged , Muscle, Skeletal/metabolism , Oxidation-Reduction , Oxygen Consumption
15.
J Viral Hepat ; 8(2): 139-47, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11264734

ABSTRACT

Interferon-alpha (IFN) has been approved as treatment for children with chronic hepatitis B (CHB). The aims of this study were to assess the impact on children's growth of the disease itself and of IFN treatment. The growth of 142 children with CHB (70 IFN-treated, 72 untreated) was monitored for a minimum of one year. Regression analysis models were used to determine which of the variables most affected children's growth. After adjusting for racial differences, the population of 142 children with CHB had a mean baseline height for age percentile of 39 and a mean baseline weight for age percentile of 38, which were significantly different (P < 0.0001) from the 50th percentiles of their respective reference populations. The height for age Z score of untreated children was inversely correlated with serum hepatitis B virus DNA and aspartate aminotransferase levels, and the weight for age Z score was inversely correlated with serum hepatitis B virus DNA levels. While undergoing IFN therapy, children displayed a "U-shaped" growth pattern, such that height for age and weight for age Z scores at 3 or 6 months were lower than scores at baseline or 12 months. In this study the average child with CHB showed compromised growth even in the absence of IFN therapy. During IFN therapy, children's growth was temporarily disrupted.


Subject(s)
Antiviral Agents/therapeutic use , Growth , Hepatitis B virus , Hepatitis B, Chronic/physiopathology , Interferon-alpha/therapeutic use , Adolescent , Body Height , Body Weight , Child , Child, Preschool , DNA, Viral/blood , Female , Growth/drug effects , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/drug therapy , Humans , Male , Racial Groups , Regression Analysis , Retrospective Studies
16.
Eur J Pediatr ; 159(7): 503-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10923223

ABSTRACT

UNLABELLED: A term infant born to consanguineous parents presented at birth with hypoglycaemia, thrombocytopenia, coagulopathy and hyperbilirubinaemia associated with polycythaemia due to delayed cord clamping. Despite phototherapy and correction of polycythaemia by partial exchange transfusion, coagulopathy, hypoglycaemia and conjugated hyperbilirubinaemia persisted, suggesting hepatic failure. Metabolic work-up led to the diagnosis of tyrosinaemia type 1 on day 4. Two--(2-nitro-4-trifluoromethylbenzoyl)--1,3 cyclohexanedione (NTBC) treatment, started on day 5, resulted in progressive clinical improvement and unambiguous biochemical response. Severe skin purpuric lesions occurred in areas exposed to phototherapy. These resolved slowly after its discontinuation. Urine analysis sampled just before and 6 days after starting NTBC treatment showed high levels of type 1 coproporphyrin isomers. Such findings do not seem directly related to tyrosinaemia type 1 where succinylacetone inhibits delta-aminolevulinic acid (delta-ALA) dehydratase and where the accumulation of delta-ALA results in neurotoxicity without photosensitivity. CONCLUSION: We describe a cutaneous form of porphyria in a neonate presenting with severe liver failure due to tyrosinaemia type 1. This porphyria is tentatively attributed to a secondary accumulation of coproporphyrins due to cholestasis, as reported in the bronze baby syndrome and recently described in neonates with purpuric phototherapy-induced eruption, rather than to a primary defect of porphyrin metabolism. The hypothesis of a direct effect of tyrosinaemia type 1 on porphyrin excretion is also discussed.


Subject(s)
Porphyria Cutanea Tarda/genetics , Tyrosinemias/genetics , Combined Modality Therapy , Consanguinity , Coproporphyrins/urine , Cyclohexanones/therapeutic use , Enzyme Inhibitors/therapeutic use , Humans , Infant, Newborn , Liver Failure/diagnosis , Liver Failure/genetics , Liver Failure/therapy , Male , Nitrobenzoates/therapeutic use , Photosensitivity Disorders/diagnosis , Photosensitivity Disorders/genetics , Photosensitivity Disorders/therapy , Phototherapy , Porphyria Cutanea Tarda/diagnosis , Porphyria Cutanea Tarda/therapy , Tyrosinemias/diagnosis , Tyrosinemias/therapy
17.
J Viral Hepat ; 7(2): 144-52, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10760045

ABSTRACT

To develop prognostic models for identifying children with hepatitis B who are likely to respond to interferon-alpha (IFN-alpha) or to spontaneously seroconvert, we evaluated results of a multinational controlled trial comprising 70 children with chronic hepatitis B who received IFN-alpha and 74 children who did not receive therapy. Prognostic models were developed using SMILES (similarity of least squares), which is a data analysis network that incorporates multidimensional relationships in the clinical data of complex diseases. Commonly collected clinical data included age, gender, serum aminotransferase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) and hepatitis B virus (HBV) DNA levels, and IFN-alpha dose. Additional data included pretreatment directional information (e.g. increases or decreases in serum aminotransferase and HBV DNA levels), liver biopsy results, race and transmission mode. Using data available prior to initiation of treatment, the SMILES models achieved prospective predictions of 89% for responders, 96% for non-responders, 100% for seroconverters and 93% for non-seroconverters. Although not predictive by themselves, the variables that had the greatest impact on predictions for IFN-alpha response were HBV DNA pretreatment direction, baseline HBV DNA, IFN-alpha dose and gender. The variables that had the greatest impact on predictions for spontaneous seroconversion were ALT pretreatment direction, baseline HBV DNA level, age and AST pretreatment direction. Therefore, these models may be useful in determining, in children with hepatitis B, the likelihood of response to IFN-alpha and spontaneous seroconversion.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis B, Chronic/therapy , Interferon-alpha/therapeutic use , Adolescent , Child , Child, Preschool , Disease Susceptibility , Female , Humans , Infant , Male , Models, Statistical , Software
18.
Gastroenterology ; 114(5): 988-95, 1998 May.
Article in English | MEDLINE | ID: mdl-9558288

ABSTRACT

BACKGROUND & AIMS: Treatment of chronic hepatitis B with interferon alfa is not approved in children. The aim of this study was to evaluate the safety and efficacy of interferon alfa (IFN-alpha) in children with chronic hepatitis B and increased transaminase levels. METHODS: Children were given either IFN-alpha2b (6 megaunits/m2 thrice weekly for 24 weeks) or no treatment. Clearance of markers of viral replication was evaluated 24 weeks after therapy and after 48 weeks of observation in controls. RESULTS: Of 149 children enrolled, 144 were evaluable (70 treated and 74 controls). Serum hepatitis B e antigen and viral DNA became negative in 26% of treated children and 11% of controls (P < 0.05). Serum aminotransferase levels normalized and liver histology improved among responders. Hepatitis B surface antigen became undetectable in 10% of treated patients and 1% of controls. Female gender and interferon treatment were the only significant predictors of response. Ethnic origin, baseline aminotransferase level, initial DNA levels, and histology did not correlate with response. Most adverse reactions were mild or moderate, and dose was reduced in 24% of children. CONCLUSIONS: In children with chronic hepatitis B, INF-alpha promotes loss of viral replication markers and surface antigen and improves aminotransferases and histology.


Subject(s)
Hepatitis B, Chronic/therapy , Interferon-alpha/therapeutic use , Adolescent , Alanine Transaminase/blood , Child , Child, Preschool , DNA, Viral/analysis , Female , Follow-Up Studies , Hepatitis B e Antigens/analysis , Hepatitis B virus/genetics , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/metabolism , Humans , Infant , Interferon-alpha/adverse effects , International Cooperation , Male , Treatment Outcome
19.
Asia Pac J Clin Nutr ; 7(2): 151-9, 1998 Jun.
Article in English | MEDLINE | ID: mdl-24393642

ABSTRACT

The objective of this study was to determine the zinc and copper status in hair of a group of Indonesian infants aged 0-5 months, a period when growth faltering in this population is known to occur, and to determine the daily zinc and copper availability in the habitual diet. A mixed cross-sectional longitudinal design was used. Infants 0-3 months of age were recruited in two villages on the south coast of the island of Madura, Indonesia and followed up to the age of 5 months. All newborns during the study period were included. Hair samples were collected between the ages of 0 and 5 months at monthly intervals. Zinc and copper concentrations were determined by flame atomic absorption spectrophotometry and compared with a sample of Belgian controls, recruited cross-sectionally. Zinc and copper content of the habitual diet was calculated on the results of a food intake study previously performed in the same community. For the 42 Madurese infants recruited, 107 hair zinc and 96 hair copper concentrations were determined. Belgian infants (15 boys, 15 girls) served as controls. One Madurese infant died during the study and six moved from the area. Hair zinc concentrations were found to decrease with age in both populations, while the zinc and copper values did not differ from the Belgian controls. Hair zinc values were not correlated with growth performance. The boys had lower hair zinc values than did the girls. Copper values among the Indonesian infants did not show a trend over time; however, the Belgian children showed an increase towards the age of 12 months, although this was not significant. The mean daily zinc and copper availability in the habitual diet was less than half of the recommended daily allowance for adult women. The situation was much worse for lactating women given that the availability of these elements increased very little. The hair zinc and copper values indicate that they are not responsible for the early onset of linear growth retardation. The lower zinc values in boys might be an indication of a marginal deficiency. The very low zinc content of the diet consumed in this population could be an indication of a zinc and copper deficit in the Madurese population, although this needs to be confirmed.

20.
Gastroenterology ; 112(2): 455-62, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9024299

ABSTRACT

BACKGROUND & AIMS: Calcium phosphate binds unconjugated bilirubin in vitro, and dietary calcium phosphate supplementation reduces the serum bilirubin level in rats with hereditary unconjugated hyperbilirubinemia (Gunn rats). The aim of this study was to evaluate the effect of oral calcium phosphate supplementation on plasma bilirubin levels in patients with Crigler-Najjar disease. METHODS: A placebo-controlled, double-blind, crossover design was used. Eleven patients, 2-42 years of age, participated. The group included 5 patients with type I disease who were all treated with phototherapy and 6 patients with type II disease who were primarily treated with phenobarbital. In addition to plasma bilirubin levels, dietary intake and urinary and fecal excretion of calcium and phosphate were evaluated. RESULTS: A modest but significant decrease in serum bilirubin was observed in patients with type I disease (18% +/- 6%, P = 0.03) but not in patients with type II disease during treatment with calcium phosphate. Urinary output of calcium and phosphate did not change during the treatment period. CONCLUSIONS: Oral calcium phosphate may be a useful adjuvant to photo-therapy in Crigler-Najjar type I disease.


Subject(s)
Calcium Phosphates/therapeutic use , Crigler-Najjar Syndrome/drug therapy , Administration, Oral , Adult , Bilirubin/blood , Calcium/urine , Calcium Phosphates/administration & dosage , Child , Child, Preschool , Crigler-Najjar Syndrome/blood , Crigler-Najjar Syndrome/urine , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Phosphates/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...